|
Neurology Development Activities
| Compound |
Development
Phase |
Method
of action |
Indication(s) |
| S-0139 |
Phase
II |
Endothelin A receptor antagonist |
Stroke |
| S-0373
|
Pre-clinical |
Thyrotropin releasing hormone analogue |
Spino-cerebellar ataxia |
Spotlight on Endothelin A Receptor
Antagonists
Endothelins are peptides that act in cerebral vessels as potent vasoconstricters,
regulating blood flow to the brain. Research indicates that cerebral levels
of endothelin increase in patients that have suffered from cerebral ischaemia
and cerebral vasospasm following subarachnoid hemorrhage. This reduced
cerebral blood flow has been linked to the neurological deficits many
patients experience following such an injury.
*Shionogi-GlaxoSmithKline,
is developing compounds that selectively inhibit the endothelin A receptor.
These endothelin A receptor antagonists are in Phase II of clinical development
for the treatment of stroke.
|
